Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03012958
Other study ID # HS-2851
Secondary ID
Status Completed
Phase
First received
Last updated
Start date July 2014
Est. completion date May 2018

Study information

Verified date January 2021
Source National Jewish Health
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The purpose of this study is to learn more about new noninvasive ways of detecting lung disease in US Military personnel and people who worked as contractors during military operations in Iraq and Afghanistan. This study is looking at conducting a type of breathing test called the lung clearance index (LCI) test which is being investigated as a potential noninvasive way to detect the type of lung disease that may be seen in symptomatic deployers retuning from Iraq and Afghanistan.


Description:

The healthy control group will comprise volunteers who are at least 18 years of age, have no history of pre-existing lung disease, and report no respiratory illness in the four weeks preceding enrollment. The symptomatic deployers who have undergone lung biopsy and meet the case definition for deployment-related lung disease. A case of deployment-related lung disease is defined as the presence of unexplained chest symptoms in a deployer who, on a surgical lung biopsy, is found to have bronchiolitis or granulomatous pneumonitis without other known cause.


Recruitment information / eligibility

Status Completed
Enrollment 73
Est. completion date May 2018
Est. primary completion date May 2018
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: For the deployer group: - presence of respiratory symptoms (cough, chest tightness, wheezing, shortness of breath or decreased exercise tolerance) following deployment - history of deployment for Operation Iraqi Freedom, Operation Enduring Freedom or Operation New Dawn for greater than or equal to 6 weeks as either military personnel or a civilian contractor - prior VATS biopsy-proven histologic abnormalities of small airways disease. For the control group: - no history of pre-existing lung disease - no respiratory illness in the four weeks preceding enrollment Exclusion Criteria: For the deployer group: - If on clinical evaluation they were found to have asthma, vocal cord dysfunction or other explanations for their respiratory symptoms and did not need to undergo surgical lung biopsy for diagnosis. - unable to provide informed consent - pregnant subjects For the control group: - pre-existing lung disease - unable to provide informed consent - pregnant subjects

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Lung clearance index (LCI)
LCI is determined by the number of lung volume turnovers necessary to clear the lungs of an inert tracer gas such as nitrogen that is inhaled at the beginning of the test. The LCI is calculated by determining the cumulative expired volume (CEV) and then dividing the CEV by the functional residual capacity. Values of less than7.0 indicate normal values while an LCI greater than 7.0 is associated with heterogeneity in ventilation and distal airway abnormalities. The ability to detect peripheral airway disease may make LCI a better modality for detecting distal airways abnormalities seen on lung histopathology but often missed on traditional pulmonary function testing.

Locations

Country Name City State
United States National Jewish Health Denver Colorado

Sponsors (1)

Lead Sponsor Collaborator
National Jewish Health

Country where clinical trial is conducted

United States, 

References & Publications (2)

Krefft SD, Strand M, Smith J, Stroup C, Meehan R, Rose C. Utility of Lung Clearance Index Testing as a Noninvasive Marker of Deployment-related Lung Disease. J Occup Environ Med. 2017 Aug;59(8):707-711. doi: 10.1097/JOM.0000000000001058. — View Citation

Zell-Baran LM, Krefft SD, Moore CM, Wolff J, Meehan R, Rose CS. Multiple breath washout test data for healthy controls. Data Brief. 2020 Dec 10;34:106641. doi: 10.1016/j.dib.2020.106641. eCollection 2021 Feb. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary LCI parameters in symptomatic deployers compared to normal adults to determine whether LCI is an early marker of lung injury. Average of three acceptable trials Up to 24 months
Secondary Correlation between LCI score and the clinical characteristics of the population of deployers. Comparison with pulmonary function testing and other clinical measures Up to 24 months
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04688905 - Diagnosing Heart Failure With Preserved Ejection Fraction in Patients With Unexplained Dyspnea (Diagnose-HFpEF)
Completed NCT03679312 - The Effect of Inhaled Nitric Oxide on Dyspnea and Exercise Tolerance in COPD Phase 1/Phase 2
Recruiting NCT04868357 - Hypnosis for the Management of Anxiety and Breathlessness During a Pulmonary Rehabilitation Program N/A
Active, not recruiting NCT03604822 - Music Therapy Protocol to Support Bulbar and Respiratory Functions in ALS N/A
Completed NCT03626519 - Effects of Menthol on Dyspnoea in COPD Patients N/A
Completed NCT02638649 - Prehospital Use of Ultrasound in Undifferentiated Shortness of Breath
Completed NCT02248831 - Evaluation of Cardiopulmonary Diseases by Ultrasound N/A
Terminated NCT02269761 - Chest Ultrasound of ER Patients With Cough or SOB
Completed NCT02538770 - Rapid Viral Diagnostics in Adults to Reduce Antimicrobial Consumption and Duration of Hospitalization N/A
Recruiting NCT01655199 - Sensitivity of the Step Test to Detect Improvement in Dyspnea Following Bronchodilation in Patients With Chronic Obstructive Pulmonary Disease N/A
Active, not recruiting NCT01440764 - Aerosol Inhalation Treatment for Dyspnea Phase 1/Phase 2
Completed NCT01577407 - Non Opioid Treatment for Experimental Dyspnea Phase 3
Completed NCT01193998 - Impact of Validated Diagnostic Prediction Model of Acute Heart Failure in the Emergency Department N/A
Recruiting NCT04327882 - Point-of-care Ultrasound Interest in Dyspneic Emergency Department Patients: an Observational Bicentric Study
Completed NCT05029986 - Preventing Dyspnea During Speech in Older Speakers N/A
Not yet recruiting NCT04181359 - The Effect of Inhaled Nitric Oxide on Dyspnea and Exercise Tolerance in Interstitial Lung Disease. Phase 1/Phase 2
Recruiting NCT04615065 - Acutelines: a Large Data-/Biobank of Acute and Emergency Medicine
Completed NCT04305639 - The Reliability and Validity of Turkish Version of ''The Dyspnea-ALS-Scale (DALS-15)"
Completed NCT04375917 - Is Reduced Hypoxia Through a Robot Intervention, Associated With Sensory and Emotional Descriptions of Dyspnea, Anxiety, Depression, Symptom Burden and Anxiolytics N/A
Completed NCT04370990 - Automated Oxygen Administration -Rethinking Interventions Alleviating Dyspnea in Patients With COPD N/A